Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

Lucia Lisi, Pierluigi Navarra, Simona Di Giambenedetto, Barbara Rossetti, Roberta Gagliardini, Manuela Colafigli, Pierfrancesco Grima, Silvia Lamonica, Alessandro D'Avino, Andrea De Luca, Genny Meini, Gaetana Sterrantino, Vincenzo Colangeli, Maria Carla Re, Alessandra Latini, Francesca Vignale, Stefano Rusconi, Valeria Micheli, Antonio Di Biagio, Giancarlo OrofinoValeria Ghisetti, Alessandra Fantauzzi, Vincenzo Vullo, Daniela Francisci, Claudio Mastroianni, Andrea Antinori, Michele Trezzi, Benedetta Canovari, Antonella D’Arminio Monforte, Maurizio Zazzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

10 Citazioni (Scopus)

Abstract

Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation arm). Results: In June 2015, 115 patients were evaluable for the primary outcome (56 study, 59 continuation arm). The study was discontinued due to excess of VF in the study arm (7 cases, 12.5%, vs 0 in the continuation arm, p = 0.005). The proportion free of treatment failure was 73.2% in the study and 59.3% in the continuation arm. Two participants in the study and 10 in the continuation arm discontinued therapy due to adverse events (p = 0.030). At VF, no emergent drug resistance was detected. Co-receptor tropism switched to non-R5 in one patient. Patients with VF reported lower adherence and had lower plasma drug levels. Femoral bone mineral density was significantly improved in the study arm. Conclusion: Switching to maraviroc with darunavir/ritonavir qd in virologically suppressed patients was associated with improved tolerability but was virologically inferior to 3-drug therapy.
Lingua originaleEnglish
pagine (da-a)e0187393-N/A
RivistaPLoS One
Volume12
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Adult
  • Agricultural and Biological Sciences (all)
  • Anti-HIV Agents
  • Antiretroviral Therapy, Highly Active
  • Biochemistry, Genetics and Molecular Biology (all)
  • Cyclohexanes
  • Darunavir
  • Drug Therapy, Combination
  • Female
  • HIV Infections
  • HIV-1
  • Humans
  • Male
  • Middle Aged
  • Ritonavir
  • Treatment Outcome
  • Triazoles
  • Viral Load

Fingerprint Entra nei temi di ricerca di 'Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial'. Insieme formano una fingerprint unica.

Cita questo